AFPmissile - An AFP-based Targeted Delivery Platform

As the industry's leading vaccine development CRO, Creative Biolabs has also conducted extensive research and exploration of vaccine delivery methods. We have therefore successfully launched a series of highly efficient vaccine delivery platforms that meet our customers' needs for vaccine delivery.

Background

One of the important reasons for the unsatisfactory clinical effect of drugs is that the drug (including small molecule targeted drugs) lacks selectivity for the site of action in the body. The targeting efficiencies of current passive and active delivery systems are still not ideal. Therefore, how to improve the selectivity of drugs to target sites, truly achieve selective and efficient drug delivery, and obtain highly effective drug therapy effects are major problems that scientists have long faced. For this problem, on the one hand, the drug itself can be modified, for example, to change the hydrophilicity of the drug to improve the ability to target tumor cells, but this method may change the efficacy of the original drug, and the cost is relatively expensive; Another way is to encapsulate the drug in a capsule, wherein the more studied carriers include nanoparticles, liposomes, emulsions, microcapsules and the like.

AFPmissile- An AFP-based Targeted Delivery Platform

During fetal development, the yolk sac and fetal liver produce a major plasma protein, AFP (also known as Alpha-fetoprotein, alpha-fetoglobulin or alpha fetal protein), which is a glycoprotein containing 591 amino acids and carbohydrate. AFP usually has two significances in clinical practice. One is to analyze the AFP content in pregnant women's blood or amniotic fluid as a test to screen certain developmental abnormalities, and the second is to be used as biomarkers to track some diseases since serum AFP levels are elevated in certain tumors.

AFPmissile is based on the second clinical significance of AFP. One fact is that most tumor cells, regardless of tumor type, are capable of expressing the AFP receptor, and they are not present or insufficient in the surface of normal cells, thus ensuring that AFP-based drugs can be targeted to tumor cells. Our AFPmissile uses pig-derived AFP as a carrier for several reasons. First, the source is homogenous. Second, compared to humans, AFP obtained from porcine source has a high degree of similarity with human AFP and there are no ethical issues; third, it is low cost. In addition to the above advantages, AFPmissile's ability to target drugs can improve the therapeutic effect of anti-tumor drugs, and because AFP receptors are not expressed or rarely expressed on normal cells, non-targeted killing of drugs is also avoided, thus significantly reduces the side effects of the drug.

Targeted delivery of anti-tumor drugs has been a hot topic for scientists. Creative Biolabs has also made a lot of explorations in this area, and finally launched a safe and efficient delivery platform - AFPmissile, which can be applied to most anti-tumor drugs. If you are interested in our technology platform, please contact us!

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.